The effect of isotretinoin on triglycerides and liver aminotransferases;Influência da isotretinoína nas transaminases hepáticas e triglicerídeos

Anais Brasileiros de Dermatologia

Volumn 87, Issue 3, 2012, Pages 382-387

  Vieira, Andreia Salezze ^a   Beijamini, Vanessa ^a   Melchiors, Ana Carolina ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Acne vulgaris; Aminotransferases; Dermatologic agents; Isotretinoin; Triglycerides

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ISOTRETINOIN; TRIACYLGLYCEROL;

ACNE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAZIL; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ACNE VULGARIS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES; TRIGLYCERIDES; YOUNG ADULT;

EID: 84863086452     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962012000300005     Document Type: Article

References (30)

1. Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J. Acne vulgaris: a disease of Western civilization. Arch Dermatol. 2002;138:1584-1590.
2. Sociedade Brasileira de Dermatologia [Internet]. Censo Dermatológico da SBD. 2006 [accessed on 29 March, 2010]. Available at: http://www.sbd.org.br/down/censo_dermatologico2006.pdf
3. Bershad SV. The Modern Age of Acne Therapy: A Review of Current Treatment Options. Mt Sinai J Med. 2001;68:279-286.
4. Sampaio S, Rivitti E. Dermatologia. São Paulo: Artes Médicas; 2001.
5. Sampaio SAP, Bagatin E. Experiência de 65 anos no tratamento da acne e de 26 anos com isotretinoína oral. An Bras Dermatol. 2009;83:361-367.
6. Ministério da Saúde. Portaria SAS/MS no 389, de 19 de setembro de 2001. Protocolo clínico e diretrizes terapêuticas. Diário oficial da União19 de set de 2001.
7. Cooper AJ. Treatment of acne with isotretinoin: recommendations based on Australian experience. Astralas J Dermatol. 2003;44:97-105.
8. Merritt B, Burkhart CN, Morrell DS. Use of isotretinoin for acne vulgares. Pediatr Ann. 2009;38:331-320.
9. Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol 2006;126:2178-2189.
10. Bozkurt B, Irkec MT, Atakan N. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. Eur J Ophthalmol. 2002;12:173-176.
11. Kaymak Y, Ilter N. The results and side effects of systemic isotretinoin treatment in 100 patients with acne vulgaris. Dermatol Nurs. 2006;18:576-580.
12. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 2006;142:1016-1022.
13. Vu-Dac N, Gervois P, Torra IP, Fruchart JC, Kosykh V, Kooistra T, et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor: contribution to the hypertriglyceridemic action of retinoids. J Clin Invest. 1998;102:625-632.
14. Júnior EDS, Sette IMF, Belém LF, Janebro DI, Pereira GJS, Barbosa JAA, et al. Isotretinoína no tratamento da acne: riscos x benefícios Rev Bras Farm. 2009;90:186-189.
15. Brito Mde F, Sant'Anna IP, Galindo JC, Rosendo LH, Santos JB. Avaliação dos efeitos adversos clínicos e alterações laboratoriais em pacientes com acne vulgar tratados com isotretinoína oral. An Bras Dermatol. 2010;85:331-337.
16. National Institutes of Health. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, Md: National Cancer Institute; 2003.
17. Teixeira MAG, França ER. Mulheres adultas com acne: aspectos comportamentais, perfis hormonal e ultra-sonográfico ovariano. Rev Bras Saúde Matern Infant. 2007;7:39-44.
18. Michaëlsson G, Vahlquist A, Mobacken H, Hersle K, Landegren J, Rönnerfält L, et al. Changes in laboratory variables induced by isotretinoin treatment of acne. Acta Derm Venereol. 1986;66:144-148.
19. Altman RS, Altman LJ, Altman JS. A Proposed Set of New Guidelines for Routine Blood Tests during Isotretinoin Therapy for Acne vulgaris. Dermatology. 2002;204:232-235.
20. Tallab T, Joharji H, Jazei M, Bahamdan K, Ibrahim K, Karkashan E. Isotretinoin therapy: any need for laboratory assessment? West Afr J Med. 2004;23:273-275.
21. Bner A, Lestringant GG, Ehlayel MS, Saarinen K, Takiddin AH. Treatment outcome of acne vulgaris with oral isotretinoin. J Coll Physicians Surg Pak. 2009;19:49-51.
22. Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B, et al. Changes in plasma lipids and lipoproteins during Isotretinoin therapy for acne. N Engl J Med. 1985;313:981-985.
23. De Marchi MA, Maranhao RC, Brandizzi LI, Souza DR. Effects of isotretinoin on the metabolism of triglyceride-rich lipoproteins and on the lipid profile in patients with acne. Arch Dermatol Res. 2006;297:403-408.
24. Rodondi N, Darioli R, Ramelet AA, Hohl D, Lenain V, Perdrix J, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis-retinoic acid therapy for acne: A pharmacogenetic study. Ann Intern Med. 2002;136:582-589.
25. McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001;45:S188-194.
26. Lestringant GG, Frossard PM, Agarwal M, Galadari IH. Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL-cholesterol. Int J Dermatol. 1997;36:859-862.
27. Ministério da Saúde. Portaria SAS/MS no 143, de 31 de março de 2010. Protocolo clínico e diretrizes terapêuticas: acne grave. Diário oficial da União 01 de abril de 2010.
28. Radcliffe JD, Czaika-Narins DM. A Comparison of the effectiveness of soy protein isolate and fish oil for reducing the severity of retinoid induced hypertriglyceridemia. Nutr Biochem. 2004;15:163-168.
29. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg. 2008;27:197-206.
30. Baxter KF, Ling TC, Barth JH, Cunliffe WJ. Retrospective survey of serum lipids in patients receiving more than three courses of isotretinoin. J Dermatolog Treat. 2003;14:216-218.